Mannan
Based on 1 publication(s) in Google Scholar
Mannan is an orally active polysaccharide compound that binds to the mannose receptor (MR). Mannan promotes bacterial uptake and endosomal degradation by binding to MR, thereby enhancing the production of IL-12 in immune cells. Mannan enhances ROS production. Mannan modulates immunity, inhibits Aflatoxin B1 (HY-N6615)-induced toxicity, and reduces lipid.
For research use only. We do not sell to patients.
- Purity: 98.4%
- CAS No.: 9036-88-8
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Mannan
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
Mannan (10-100 μg/mL, 30 min) enhances the IL-12 production by increasing bacterial uptake and endosomal degradation in L. acidophilus and S. aureus stimulated dendritic cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Murine bone marrow-derived dendritic cells (BMDCs)
-
Concentration:10 µg/mL, 100 µg/mL
-
Incubation Time:30 min for pretreatment before bacteria stimulation; 60 min before adding bacteria for endocytosis assay; 1 h for MR surface expression assay
-
Result:Led to a decrease in the surface expression of the mannose receptor (MR) detected.
-
Cell Line:Murine bone marrow-derived dendritic cells (BMDCs)
-
Concentration:10 µg/mL, 100 µg/mL
-
Incubation Time:30 min for pretreatment before bacteria stimulation; 60 min before adding bacteria for endocytosis assay; 1 h for MR surface expression assay
-
Result:Increased the expression of IFN-β in cells stimulated with L. acidophilus.
Mannan (50-100 mg/kg; i.p.; 2-5 times) reduces serum levels of low-density lipoprotein (LDL), cholesterol, and triglycerides in mice with acute dyslipidemia induced by poloxamer 407 (HY-D1005)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male CBA/Lac mice (2.5-3-month-old, weighing 22-25 g), acute lipemia induced by poloxamer 407 model[4]
-
Dosage:50 mg/kg, 100 mg/kg
-
Administration:Intraperitoneal injection, 5 times at 50 mg/kg every other day or 2 times at 100 mg/kg with 1-day interval
-
Result:Reduced the levels of triglyceride, atherogenic LDL, and total cholesterol in the serum at 50 mg/kg and 100 mg/kg.
Decreased the triglyceride concentration in the liver.
Increased the lability of lysosomal membranes in the liver and elevated the serum activity of chitotriosidase, a marker of macrophage activation.
Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Administration: Mannan (10 or 20 mg in 200 μL PBS) • i.p. • either only on day 0 or for multiple exposures additionally on days 7 and 14
Mice: Pla1a-/- mice • 12-13 weeks
Administration: Mannan (20 mg in 200 μL PBS) • i.p. • dose on days 0, 4, and 8
Mice: EDIL3-knockout mice
Administration: Mannan (20 mg in 200 μL PBS) • i.p. • dose on days 1, 2, and 3
Cellular changes: Increased infiltration/activation of MoDCs, γδ T cells, and Th17 cells
Skin phenotype: Erythema, plaques, and scaling on paws and ears, Onycholysis and alopecia in affected areas
Histology analysis: Hyperkeratosis, acanthosis, and subcorneal microabscesses (neutrophil accumulation), Synovial hyperplasia, inflammatory infiltration, mild cartilage erosion, entheseal new bone formation, and osteoclasts (TRAP⁺)
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 9036-88-8
-
Appearance Solid
-
Color White to light yellow
-
SMILES
[Mannan]
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Eur J Immunol
Invariant natural killer T cells drive hepatic homeostasis in nonalcoholic fatty liver disease via sustained IL-10 expression in CD170+ Kupffer cells. [Abstract]2023 Nov;53(11):e2350474. PMID: 37489253
Solvent & Solubility
H2O : 50 mg/mL (Need ultrasonic)
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Mathiesen R, et al. Mannan Enhances IL-12 Production by Increasing Bacterial Uptake and Endosomal Degradation in L. acidophilus and S. aureus Stimulated Dendritic Cells. Front Immunol. 2019 Nov 15;10:2646. [Content Brief]
[2]. Madrigal-Santillán E, et al. Inhibitory effect of mannan on the toxicity produced in mice fed aflatoxin B1 contaminated corn. Arch Environ Contam Toxicol. 2007 Oct;53(3):466-72. [Content Brief]
[3]. Funayama H, et al. Pharmacological characterization of anaphylaxis-like shock responses induced in mice by mannan and lipopolysaccharide. Int Immunopharmacol. 2009 Dec;9(13-14):1518-24. [Content Brief]
[4]. Goncharova NV, et al. Hypolipidemic Effect of Mannan in Mice with Acute Lipemia Induced by Poloxamer 407. Bull Exp Biol Med. 2016 Nov;162(1):18-22. [Content Brief]
[5]. Khmaladze Ia, et al. Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3669-78. [Content Brief]
[6]. Zhao Y, et al. Phospholipase A1 Member A Deficiency Alleviates Mannan-Induced Psoriatic Arthritis in Mice Model. Int J Mol Sci. 2022 Aug 2;23(15):8559. [Content Brief]
[7]. Yu J, et al. EDIL3 alleviates Mannan-induced psoriatic arthritis by slowing the intracellular glycolysis process in mononuclear-derived dendritic cells. Inflammation. 2025 Aug;48(4):1671-1688. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mannan Related Classifications
HY-W145667 Related Classifications
Powered by Bioz